# NEOAVAX (NCT03341845)

> Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

No report yet. It can be ordered.

- Drugs tested: axitinib plus avelumab
- Indication: localized clear-cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03341845
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: The Netherlands Cancer Institute
- Conditions: Renal Cell Carcinoma
- Interventions: Axitinib; Avelumab
- Enrollment: 40
- Primary outcome: number of patients with partial remission

## Indexed commentary on NEOAVAX so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 2
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=neoavax-nct03341845

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03341845", "email": "<work email>"}; the inbox owner confirms by the emailed link.